Hospital-Treated Gram-Negative Infections | Access and Reimbursement | US | 2016
Gram-Negative Infections | Access & Reimbursement | US examines the market access factors that influence commercial success of therapies for the treatment of gram-negative infections. The analysis is based on primary research data from U.S. ID specialists, non-ID specialists, and hospital pharmacy directors. This research explores how payers and physicians interact, how P&T committees reach hospital formulary decisions on antibiotics, and how reimbursement decisions impact the prescribing and uptake of specific therapies at the brand level. We also analyze the impact of antimicrobial stewardship programs on the market uptake of premium-priced novel antibiotics, especially given the waning utility of current agents due to the rising prevalence of drug-resistant gram-negative pathogens (GNPs).
